Micronuclei are small structures in the cell that contain fragments of genetic material. These structures are prone to rupturing spontaneously and usually form in cells, such as cancer cells, which have experienced stress or DNA damage.
They are found in addition to a cell's main nucleus, which contains most of the cell's genetic material.
Micronuclei are known to play a role in inflammation following DNA damage, which both speeds up cancer development and determines the effectiveness of cancer treatments. When micronuclei rupture, they are recognized by a protein called cGAS that binds to them and initiates an inflammatory response.
"Not all ruptured micronuclei recruit cGAS," says Kate MacDonald, a PhD student in Dr. Harding's lab and first author of the study. "We think that there are a set of micronuclei characteristics – which remain poorly understood – that can lead to cGAS recruitment and inflammation."
To understand these features, the team looked at how different types of stress and DNA damage-inducing treatments affect the ability of the micronuclei to attract and activate cGAS.
They found that whether or not cGAS can recognize and respond to ruptured micronuclei depends on what caused the DNA damage that led to the micronuclei in the first place.
"This work has important implications for how the genetic material is arranged in the cell before and after exposure to cancer treatments that damage DNA," says Dr. Harding. “We also think micronuclei features may determine how cancers develop in the first place.
"Understanding these molecular processes could lead to new ways to harness the impacts of micronuclei on cellular biology – and could ultimately lead to better cancer treatments with less side effects," adds Dr. Harding, who is also an assistant professor in the Department of Medical Biophysics at the University of Toronto.
This work was supported by the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, the JP Bickell Foundation, the Province of Ontario, the University of Toronto, the Structural Genomics Consortium and The Princess Margaret Cancer Foundation.
Read more about the study
This story first appeared on UHN News